{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:59:00Z","timestamp":1790985540804,"version":"4.1.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008903","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["MOHW112-TDU-B-222-124016"],"award-info":[{"award-number":["MOHW112-TDU-B-222-124016"]}],"id":[{"id":"10.13039\/100008903","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008903","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["MOHW114-TDU-B-222-144016"],"award-info":[{"award-number":["MOHW114-TDU-B-222-144016"]}],"id":[{"id":"10.13039\/100008903","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008903","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["MOHW114-TDU-B-222-000020"],"award-info":[{"award-number":["MOHW114-TDU-B-222-000020"]}],"id":[{"id":"10.13039\/100008903","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008903","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["MOHW113-TDU-B-222-134016"],"award-info":[{"award-number":["MOHW113-TDU-B-222-134016"]}],"id":[{"id":"10.13039\/100008903","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008903","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["MOHW111-TDU-B-221-114016"],"award-info":[{"award-number":["MOHW111-TDU-B-221-114016"]}],"id":[{"id":"10.13039\/100008903","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC112-2639-B-039-001-ASP"],"award-info":[{"award-number":["NSTC112-2639-B-039-001-ASP"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC113-2639-B-039-001-ASP"],"award-info":[{"award-number":["NSTC113-2639-B-039-001-ASP"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["MOST110-2639-B-039-001-ASP"],"award-info":[{"award-number":["MOST110-2639-B-039-001-ASP"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC113-2639-B-039-001"],"award-info":[{"award-number":["NSTC113-2639-B-039-001"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["MOST110-2639-B-039-001"],"award-info":[{"award-number":["MOST110-2639-B-039-001"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC112-2639-B-039-001"],"award-info":[{"award-number":["NSTC112-2639-B-039-001"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["MOST111-2314-B-039-055-MY3"],"award-info":[{"award-number":["MOST111-2314-B-039-055-MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC113-2314-B-039-004"],"award-info":[{"award-number":["NSTC113-2314-B-039-004"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC113-2634-F-039-001"],"award-info":[{"award-number":["NSTC113-2634-F-039-001"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC113-2314-B-039-029"],"award-info":[{"award-number":["NSTC113-2314-B-039-029"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007300","name":"China Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007300","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010002","name":"Ministry of Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.canlet.2025.217912","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T13:37:56Z","timestamp":1752586676000},"page":"217912","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Deglycosylated PD-L1 is a biomarker for immune checkpoint blockade response: a real-world study in breast cancer patients in Taiwan"],"prefix":"10.1016","volume":"631","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5477-1682","authenticated-orcid":false,"given":"Shao-Chun","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5557-8043","authenticated-orcid":false,"given":"Yi-Chun","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Ren","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu","family":"Ou-Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Yi","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang-Chih","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1209-3043","authenticated-orcid":false,"given":"Kun-Ming","family":"Rau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long-Sheng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Cheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Shen","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Shen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Wen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Po","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Jung","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Wen","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2443-8151","authenticated-orcid":false,"given":"Hong-Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chung","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsai-Chung","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tai-Lung","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1082-679X","authenticated-orcid":false,"given":"Guo-Shiou","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Fang","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiun-Sheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Ming","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5274-9131","authenticated-orcid":false,"given":"Jeng-Fong","family":"Chiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyr-Ming","family":"Sheen-Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Fung","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4317-4740","authenticated-orcid":false,"given":"Mien-Chie","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2025.217912_bib1","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.coi.2016.07.005","article-title":"Neoantigens encoded in the cancer genome","volume":"41","author":"Schumacher","year":"2016","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.canlet.2025.217912_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2019.101947","article-title":"Breast cancer vaccines: heeding the lessons of the past to guide a path forward","volume":"84","author":"Solinas","year":"2020","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.canlet.2025.217912_bib3","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1200\/JCO.18.01010","article-title":"Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers","volume":"37","author":"Loi","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217912_bib4","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1093\/annonc\/mdz007","article-title":"Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer","volume":"30","author":"Dieci","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2025.217912_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2019.102855","article-title":"Triple negative breast cancer: a thorough review of biomarkers","volume":"145","author":"da Silva","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.canlet.2025.217912_bib6","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1053\/j.seminoncol.2021.09.002","article-title":"A review of immune checkpoint blockade in breast cancer","volume":"48","author":"Pellegrino","year":"2021","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.canlet.2025.217912_bib7","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa1814213","article-title":"Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer","volume":"380","author":"Bardia","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.217912_bib8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1513749","article-title":"Adaptive randomization of veliparib-carboplatin treatment in breast cancer","volume":"375","author":"Rugo","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.217912_bib9","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.217912_bib10","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.217912_bib11","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.217912_bib12","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1200\/JCO.2009.23.7370","article-title":"Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer","volume":"28","author":"Denkert","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217912_bib13","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1200\/JCO.2014.58.1967","article-title":"Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers","volume":"33","author":"Denkert","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217912_bib14","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/2326-6066.CIR-14-0133","article-title":"PD-L1 expression correlates with tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer","volume":"3","author":"Wimberly","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.canlet.2025.217912_bib15","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.tranon.2018.01.011","article-title":"A comprehensive immunologic portrait of triple-negative breast cancer","volume":"11","author":"Liu","year":"2018","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.canlet.2025.217912_bib16","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/nrclinonc.2015.215","article-title":"Clinical relevance of host immunity in breast cancer: from TILs to the clinic","volume":"13","author":"Savas","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217912_bib17","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.humpath.2015.09.003","article-title":"PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas","volume":"47","author":"Cimino-Mathews","year":"2016","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.canlet.2025.217912_bib18","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/nrd.2018.210","article-title":"The clinical trial landscape for PD1\/PDL1 immune checkpoint inhibitors","volume":"17","author":"Tang","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2025.217912_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216726","article-title":"PD-1 regulation in immune homeostasis and immunotherapy","volume":"588","author":"Gao","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.217912_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216969","article-title":"The opportunities and challenges of using PD-1\/PD-L1 inhibitors for leukemia treatment","volume":"593","author":"Xu","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.217912_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217498","article-title":"Regulation of PD-L1 glycosylation and advances in cancer immunotherapy","volume":"612","author":"Lee","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.217912_bib22","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.canlet.2025.217912_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216318","article-title":"The opportunities and challenges in immunotherapy: insights from the regulation of PD-L1 in cancer cells","volume":"569","author":"Lin","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.217912_bib24","doi-asserted-by":"crossref","first-page":"S1147","DOI":"10.1016\/j.annonc.2020.08.2243","article-title":"LBA15 primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC); atezolizumab (atezo) for unresectable locally advanced\/metastatic triple-negative breast cancer (mTNBC)","volume":"31","author":"Miles","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2025.217912_bib25","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2025.217912_bib26","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous Non\u2013small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.217912_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0130142","article-title":"Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed Death-Ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers","volume":"10","author":"Carbognin","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2025.217912_bib28","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.critrevonc.2016.02.001","article-title":"PD-L1 expression in cancer patients receiving anti PD-1\/PD-L1 antibodies: a systematic review and meta-analysis","volume":"100","author":"Gandini","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.canlet.2025.217912_bib29","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1007\/s00432-022-04286-6","article-title":"PD-1\/PD-L1 inhibitors in treatment-na\u00efve, advanced non-small cell lung cancer patients with < 1% PD-L1 expression: a meta-analysis of randomized controlled trials","volume":"149","author":"Wankhede","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217912_bib30","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ccell.2019.06.008","article-title":"Removal of N-Linked glycosylation enhances PD-L1 detection and predicts Anti-PD-1\/PD-L1 therapeutic efficacy","volume":"36","author":"Lee","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2025.217912_bib31","doi-asserted-by":"crossref","DOI":"10.1177\/15330338211019442","article-title":"Removal of N-Linked glycosylation enhances PD-L1 detection in Colon cancer: validation research based on immunohistochemistry analysis","volume":"20","author":"Xu","year":"2021","journal-title":"Technol. Cancer Res. Treat."},{"key":"10.1016\/j.canlet.2025.217912_bib32","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12943-020-01304-4","article-title":"A comparability study of natural and deglycosylated PD-L1 levels in lung cancer: evidence from immunohistochemical analysis","volume":"20","author":"Mei","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2025.217912_bib33","first-page":"123","article-title":"De-glycosylated membrane PD-L1 in tumor tissues as a biomarker for responsiveness to atezolizumab (Tecentriq) in advanced breast cancer patients","volume":"12","author":"Ou-Yang","year":"2022","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.canlet.2025.217912_bib34","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12929-020-00670-x","article-title":"The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis","volume":"27","author":"Wang","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.canlet.2025.217912_bib35","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ccell.2018.01.009","article-title":"Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1","volume":"33","author":"Li","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2025.217912_bib36","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/s41467-018-04313-6","article-title":"STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion","volume":"9","author":"Hsu","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2025.217912_bib37","doi-asserted-by":"crossref","first-page":"6349","DOI":"10.1158\/0008-5472.CAN-18-1892","article-title":"Posttranslational modifications of PD-L1 and their applications in cancer therapy","volume":"78","author":"Hsu","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2025.217912_bib38","article-title":"Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity","volume":"7","author":"Li","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2025.217912_bib39","article-title":"An optimized protocol for PD-L1 pathological assessment with patient sample deglycosylation to improve correlation with therapeutic response","volume":"3","author":"Wang","year":"2022","journal-title":"STAR Protocols"},{"key":"10.1016\/j.canlet.2025.217912_bib40","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and Nab-Paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.217912_bib41","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","article-title":"Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer","volume":"32","author":"Miles","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2025.217912_bib42","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005573","article-title":"Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types","volume":"10","author":"Maule","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2025.217912_bib43","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.humpath.2020.11.004","article-title":"Comparison of three FDA-approved diagnostic immunohistochemistry assays of PD-L1 in triple-negative breast carcinoma","volume":"108","author":"Huang","year":"2021","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.canlet.2025.217912_bib44","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/gme.0b013e31824d8f40","article-title":"Executive summary of the stages of reproductive aging workshop + 10: addressing the unfinished agenda of staging reproductive aging","volume":"19","author":"Harlow","year":"2012","journal-title":"Menopause"},{"key":"10.1016\/j.canlet.2025.217912_bib45","doi-asserted-by":"crossref","first-page":"15","DOI":"10.17305\/bjbms.2022.7953","article-title":"PD-L1 testing by immunohistochemistry in immuno-oncology","volume":"23","author":"Vranic","year":"2023","journal-title":"Biomol. Biomed."},{"key":"10.1016\/j.canlet.2025.217912_bib46","doi-asserted-by":"crossref","first-page":"6453","DOI":"10.1158\/1078-0432.CCR-20-2085","article-title":"Spatial and temporal heterogeneity of PD-L1 expression and tumor mutational burden in gastroesophageal adenocarcinoma at baseline diagnosis and after chemotherapy","volume":"26","author":"Zhou","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2025.217912_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.825284","article-title":"Regulation of intrinsic functions of PD-L1 by post-translational modification in tumors","volume":"12","author":"Nihira","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2025.217912_bib48","article-title":"Advances and prospects of biomarkers for immune checkpoint inhibitors","volume":"5","author":"Yamaguchi","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.canlet.2025.217912_bib49","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/CJI.0000000000000275","article-title":"Variation of programmed death ligand 1 expression after platinum-based neoadjuvant chemotherapy in lung cancer","volume":"42","author":"Guo","year":"2019","journal-title":"J. Immunother."},{"key":"10.1016\/j.canlet.2025.217912_bib50","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.canlet.2019.08.005","article-title":"Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer","volume":"464","author":"Fournel","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.217912_bib51","doi-asserted-by":"crossref","first-page":"7383","DOI":"10.2147\/IJGM.S381530","article-title":"The clinical significance of deglycosylated PD-L1 level detection using 28-8 monoclonal antibody in lung adenocarcinoma","volume":"15","author":"Wang","year":"2022","journal-title":"Int. J. Gen. Med."},{"key":"10.1016\/j.canlet.2025.217912_bib52","doi-asserted-by":"crossref","first-page":"15958","DOI":"10.1021\/acs.analchem.1c03287","article-title":"In situ visualization of PD-L1-Specific glycosylation on tissue sections","volume":"93","author":"Huang","year":"2021","journal-title":"Anal. Chem."},{"key":"10.1016\/j.canlet.2025.217912_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100220","article-title":"Impact of decalcification, cold ischemia, and deglycosylation on performance of programmed cell death Ligand-1 antibodies with different binding epitopes: comparison of 7 clones","volume":"36","author":"Lawson","year":"2023","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.canlet.2025.217912_bib54","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/s41379-019-0372-z","article-title":"Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies","volume":"33","author":"Lawson","year":"2020","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.canlet.2025.217912_bib55","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00428-022-03369-6","article-title":"Deglycosylation of pathological specimens alters performance of diagnostic PDL1 antibodies","volume":"481","author":"Dressler","year":"2022","journal-title":"Virchows Arch."},{"key":"10.1016\/j.canlet.2025.217912_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100159","article-title":"Tissue age affects antigenicity and scoring for the 22C3 immunohistochemistry companion diagnostic test","volume":"36","author":"Fernandez","year":"2023","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.canlet.2025.217912_bib57","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/0008-5472.CAN-19-3133","article-title":"Targeting glycosylated PD-1 induces potent antitumor immunity","volume":"80","author":"Sun","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2025.217912_bib58","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/430030a","article-title":"Cancer: understanding the target","volume":"430","author":"Stratton","year":"2004","journal-title":"Nature"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438352500480X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438352500480X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:55:04Z","timestamp":1778684104000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030438352500480X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":58,"alternative-id":["S030438352500480X"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2025.217912","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Deglycosylated PD-L1 is a biomarker for immune checkpoint blockade response: a real-world study in breast cancer patients in Taiwan","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2025.217912","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"217912"}}